Lung-cancer immunotherapy gets its close-up at oncology meeting

Even before the ASCO meeting opened today, the industry has been abuzz about the breakthrough potential of new immunotherapies to restore immune attacks on cancers. Report

Suggested Articles

FDA
Pharma

AZ advances toward $3B sales target with first-line Tagrisso nod

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

by Carly Helfand
fda
Regulatory

Ultragenyx nabs FDA nod for $200K-per-year Crysvita

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

by Eric Sagonowsky
Roche
Pharma

Roche gets double dose of good Hemlibra news

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.

by Carly Helfand